To print: Select File and then Print from your browser's menu

Title: Sibutramine Promising Treatment for Obese Patients with Binge Eating Disorders

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=14609886

Arch Gen Psychiatry 2003 Nov;60:11:1109-16. "A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder"
11/25/2003 09:02:00 AM
By Deanna M Green, PhD

Obese patients with binge eating disorder (BED) treated with sibutramine show a reduction in weight, depression, and binge frequency and severity, say researchers. Associated with psychiatric conditions such as depression, BED is a newly recognised condition that commonly affects obese patients. Pharmacologic intervention has most often included anti-depressant and anticonvulsant agents. Jose C Appolonario, MD, DSc, and colleagues at the Federal University of Rio de Janeiro, Brazil, evaluated the effectiveness of the anti-obesity agent sibutramine in obese patients with BED. Sibutramine induces weight loss by physiological effects on satiety and thermogenesis. The double-blind study included 60 patients (53 women, mean age 36) with a BMI between 30 and 45 kg/m[² who were confirmed to have BED. Patients were randomised to receive either sibutramine hydrochloride (15 mg/day) or placebo for 12 weeks. A 66% decrease in binge days was seen with patients in the sibutramine group, compared to only a 41% decrease in patients in the placebo group. This effect was noted after only 2 weeks and was maintained throughout treatment. A concomitant effect on weight was also observed. Patients given sibutramine lost on average 7.4 kg by week 12 and placebo patients gained 1.4 kg (P < .001). Weight loss correlated significantly with a decrease in binge frequency. A significant reduction in depressive symptoms also occurred during sibutramine treatment. Beck Depression Inventory scores decreased by 43% in patients taking sibutramine and by only 4% in the control group. Dry mouth and constipation were the only adverse events associated with sibutramine. No effects on systolic or diastolic blood pressure were seen; though an increase in heart rate was recorded. Dr. Appolonario concludes that "sibutramine [was] effective in reducing binge eating, body weight and associated depressive symptoms in [this] short-term study." "Sibutramine is a promising agent to be used in obese patients with binge eating disorder," though "these preliminary findings need to be further replicated," he adds.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=14609886

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.